| Gateway Hospice 103 2nd Avenue Ne, Clarion, IA, 50525 | |
| (515) 408-5041 |
News Archive
Researchers at the University of British Columbia and the Paul Scherrer Institut in Switzerland have created a microneedle drug monitoring system that could one day replace costly, invasive blood draws and improve patient comfort.
U.S. Department of Health and Human Services Secretary Kathleen Sebelius today announced the release of $101 million in emergency contingency funding to help eligible low-income homeowners and renters meet their home energy needs.
Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.
The Wall Street Journal reports that, according to experts and private studies, "[m]any urban hospitals lack sufficient medical staff, beds, equipment and 'surge' plans to provide optimal care for potentially hundreds or thousands of patients from a large bombing, emergency and trauma doctors say."
An experimental treatment for sickle cell disease developed at the Los Angeles Biomedical Research Institute has entered Phase 3 clinical trials, David I. Meyer, PhD, LA BioMed president and CEO announced today.
› Verified 9 days ago
| Name | Gateway Hospice |
|---|---|
| Location | 103 2nd Avenue Ne, Clarion, Iowa |
| Hospice ID | 161556 |
| Category | Part of a Home Health Agency |
| Ownership Type | Government - County |
| Profit Type | GEVERNMENT |
| SSA county code | 980 |
News Archive
Researchers at the University of British Columbia and the Paul Scherrer Institut in Switzerland have created a microneedle drug monitoring system that could one day replace costly, invasive blood draws and improve patient comfort.
U.S. Department of Health and Human Services Secretary Kathleen Sebelius today announced the release of $101 million in emergency contingency funding to help eligible low-income homeowners and renters meet their home energy needs.
Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.
The Wall Street Journal reports that, according to experts and private studies, "[m]any urban hospitals lack sufficient medical staff, beds, equipment and 'surge' plans to provide optimal care for potentially hundreds or thousands of patients from a large bombing, emergency and trauma doctors say."
An experimental treatment for sickle cell disease developed at the Los Angeles Biomedical Research Institute has entered Phase 3 clinical trials, David I. Meyer, PhD, LA BioMed president and CEO announced today.
› Verified 9 days ago
| NPI Number | 1023479813 |
| Organization Name | Heartland Healthcare, Inc. |
| Address | 103 2nd Ave Ne Clarion, Iowa, 50525 |
| Phone Number | (208)401-1400 |
News Archive
Researchers at the University of British Columbia and the Paul Scherrer Institut in Switzerland have created a microneedle drug monitoring system that could one day replace costly, invasive blood draws and improve patient comfort.
U.S. Department of Health and Human Services Secretary Kathleen Sebelius today announced the release of $101 million in emergency contingency funding to help eligible low-income homeowners and renters meet their home energy needs.
Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.
The Wall Street Journal reports that, according to experts and private studies, "[m]any urban hospitals lack sufficient medical staff, beds, equipment and 'surge' plans to provide optimal care for potentially hundreds or thousands of patients from a large bombing, emergency and trauma doctors say."
An experimental treatment for sickle cell disease developed at the Los Angeles Biomedical Research Institute has entered Phase 3 clinical trials, David I. Meyer, PhD, LA BioMed president and CEO announced today.
› Verified 9 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 100.0 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 100.0 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 70.0 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 94.6 | 97.3 |
| Patients who got timely treatment for shortness of breath | Not Available | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | Not Available | 93.3 |
News Archive
Researchers at the University of British Columbia and the Paul Scherrer Institut in Switzerland have created a microneedle drug monitoring system that could one day replace costly, invasive blood draws and improve patient comfort.
U.S. Department of Health and Human Services Secretary Kathleen Sebelius today announced the release of $101 million in emergency contingency funding to help eligible low-income homeowners and renters meet their home energy needs.
Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.
The Wall Street Journal reports that, according to experts and private studies, "[m]any urban hospitals lack sufficient medical staff, beds, equipment and 'surge' plans to provide optimal care for potentially hundreds or thousands of patients from a large bombing, emergency and trauma doctors say."
An experimental treatment for sickle cell disease developed at the Los Angeles Biomedical Research Institute has entered Phase 3 clinical trials, David I. Meyer, PhD, LA BioMed president and CEO announced today.
› Verified 9 days ago
| Home Health Aides | 0.75 |
| Counselors | 1 |
| Homemakers | 0.25 |
| Medical Social Workers | 1.1 |
| Physicians | 0.1 |
| Registered Nurses | 3.2 |
| Other Personnel | 0.13 |
| Total Employees | 6.53 |
|---|
News Archive
Researchers at the University of British Columbia and the Paul Scherrer Institut in Switzerland have created a microneedle drug monitoring system that could one day replace costly, invasive blood draws and improve patient comfort.
U.S. Department of Health and Human Services Secretary Kathleen Sebelius today announced the release of $101 million in emergency contingency funding to help eligible low-income homeowners and renters meet their home energy needs.
Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.
The Wall Street Journal reports that, according to experts and private studies, "[m]any urban hospitals lack sufficient medical staff, beds, equipment and 'surge' plans to provide optimal care for potentially hundreds or thousands of patients from a large bombing, emergency and trauma doctors say."
An experimental treatment for sickle cell disease developed at the Los Angeles Biomedical Research Institute has entered Phase 3 clinical trials, David I. Meyer, PhD, LA BioMed president and CEO announced today.
› Verified 9 days ago
| Gateway Hospice Location: 103 2nd Avenue Ne, Clarion, Iowa, 50525 Phone: (515) 408-5041 |